Sign in

You're signed outSign in or to get full access.

ST

SEELOS THERAPEUTICS, INC. (SEEL)·Q4 2017 Earnings Summary

Executive Summary

  • Q4 2017 was dominated by a regulatory setback: the FDA issued a Complete Response Letter (CRL) for Vitaros, prompting Apricus (now Seelos Therapeutics, SEEL) to request an end‑of‑review meeting (targeted for April 2018) to determine the pathway to address DDAIP safety concerns .
  • Sequential financial improvement: net loss narrowed to $2.4M (EPS −$0.16) vs. Q3’s $3.8M (EPS −$0.29), aided by lower near‑term R&D and G&A spend, though YoY Q4 loss increased vs. Q4 2016 (−$0.3M; EPS −$0.04) .
  • Liquidity remained stable at $6.3M (Dec 31 and Feb 26), with management expecting cash runway through year‑end 2018 and a plan to reduce expenses and explore business combinations to maximize shareholder value amid regulatory uncertainty .
  • Stock reaction catalysts: resolution of FDA safety concerns on DDAIP concentration, clarity on potential reformulation/nonclinical requirements, and any partnering or strategic transaction updates; Allergan’s commercialization option remains contingent on approval and is thus on hold .

What Went Well and What Went Wrong

What Went Well

  • Management secured a stable cash position and reiterated a runway through 2018: “As of February 26, 2018, the Company’s cash totaled $6.3 million, which is expected to fund operations through the end of 2018” .
  • Clear regulatory engagement plan: Apricus will “submit a request to the FDA for an end‑of‑review meeting… expected to be scheduled in April” to address CRL deficiencies, focusing on DDAIP safety .
  • Balance sheet strengthened in 2017 by the Ferring ex‑U.S. Vitaros transaction ($12.3M gain), offsetting operating expenses and enabling optionality while pursuing regulatory clarity .

What Went Wrong

  • FDA CRL for Vitaros in the U.S., with gating safety concerns (DDAIP tumor promotion and STI transmission) and new CMC issues; management acknowledged “extremely disappointed” and prioritized addressing these items first .
  • Sequential cash decline vs. Q3 (from $8.5M at 9/30 to $6.3M at 12/31), highlighting the need for cost controls while awaiting FDA guidance .
  • YoY Q4 deterioration: net loss widened to $2.4M vs. $0.3M in Q4 2016, reflecting milestone payments and preparation activities tied to the NDA cycle .

Financial Results

Quarterly Headline Results

MetricQ4 2016Q2 2017Q3 2017Q4 2017
Net Income (Loss) ($USD Millions)−$0.3 −$1.474 −$3.832 −$2.4
EPS ($USD)−$0.04 −$0.13 −$0.29 −$0.16

Notes:

  • Q3 loss included a $1.5M regulatory milestone to Allergan upon FDA acknowledgment of the resubmission .
  • For all periods, ex‑U.S. Vitaros operations are presented as discontinued operations .

Liquidity Progression

MetricJun 30 2017Sep 30 2017Dec 31 2017Feb 26 2018
Cash ($USD Millions)$7.821 $8.463 $6.331 $6.3

Operating Expenses (Quarter Detail Where Available)

Metric ($USD Thousands)Q2 2017Q3 2017
Research & Development$(839) $(1,960)
General & Administrative$(1,602) $(1,756)

Full-Year 2017 (Context)

Metric ($USD Thousands)FY 2017FY 2016
R&D Expense$(3,463) $(5,880)
G&A Expense$(7,210) $(7,778)
Loss from Continuing Ops$(11,747) $(7,645)
Income from Discontinued Ops$12,070 $226
Net Income (Loss)$323 $(7,419)
EPS (Total)$0.02 $(1.15)

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Vitaros U.S. regulatory milestoneQ1 2018PDUFA goal date Feb 17, 2018 FDA CRL received; end‑of‑review meeting expected April 2018 Lowered (approval timeline reset)
Cash runway2018Runway through end of 2018 (Q3 update) Runway through end of 2018 reaffirmed Maintained
Operating focus2018Prepare for commercialization; ongoing FDA dialogue Reduce expenses, explore business combinations, prioritize addressing DDAIP safety Reoriented to preservation/strategic options

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 & Q3)Current Period (Q4)Trend
FDA/Vitaros regulatory pathQ2: Final NDA draft; resubmission expected; 6‑month review cadence • Q3: Resubmitted; PDUFA Feb 17, 2018; confident deficiencies addressed FDA CRL citing DDAIP safety and new CMC issues; end‑of‑review meeting in April Deteriorated (setback; roadmap reset)
DDAIP safety (tumor promotion, STI transmission)Limited prior emphasis (global safety database cited) Gating issue; options include reducing DDAIP concentration or new nonclinical studies Elevated concern; requires mitigation
Commercial planning/Allergan optionOngoing preparation; Allergan has 60‑day post‑approval opt‑in right ($20M upfront, milestones, royalties) Allergan engagement continues but contingent on approval; focus shifted to regulatory fix On hold pending regulatory outcome
Cash/expense managementExtended runway; regained NASDAQ compliance; fundraising Runway through 2018; further cost reductions planned Defensive posture sustained
Business development (RayVa)Active partnering process; ex‑U.S. partner focus Strategic flexibility prioritized; RayVa partnering remains a priority but intertwined with Vitaros outcome Continuity; dependent on Vitaros path

Management Commentary

  • “We will submit a request to the FDA for an end‑of‑review meeting… Our objective for this meeting is to determine the specific requirements needed to address the deficiencies noted in the Complete Response.” — CEO Richard Pascoe .
  • “The FDA continues to question whether the overall risk benefit profile of Vitaros outweighs the safety concerns… specifically… DDAIP… tumor promoter… enhance the transmission of sexually transmitted infections.” — CEO .
  • “One potential pathway… lowering the concentration of the DDAIP… or… additional nonclinical studies… if we had to reformulate… we would have to run at a minimum some type of bridging study.” — Executive Director of Finance Kelly Deck .
  • “As of February 26, 2018, the Company’s cash totaled $6.3 million… expected to fund operations through the end of 2018.” — Press release .

Q&A Highlights

  • DDAIP pathway options: management outlined reformulation (lower concentration) vs. nonclinical studies; a bridging study would be required if formulation is changed .
  • Real‑world safety: no observed signals in ex‑U.S. experience related to tumor promotion/STI transmission; issue is specific to FDA’s U.S. review standards .
  • Cash burn and priorities: expense reductions and deferral of noncritical R&D until FDA guidance; runway through 2018 reiterated .
  • Allergan’s role: Apricus obligated to collaborate on U.S. Vitaros; Allergan would decide post‑approval; if Apricus opts not to continue, rights could revert as an option .

Estimates Context

  • Wall Street consensus (S&P Global) for Q4 2017 EPS and revenue was unavailable for SEEL due to missing CIQ mapping in our S&P Global integration; therefore, comparisons vs consensus cannot be provided at this time. We attempted retrieval but received an error indicating no CIQ mapping for ticker SEEL. As a result, any estimate‑based beat/miss analysis is not possible in this recap [GetEstimates attempt error].

Key Takeaways for Investors

  • Regulatory trajectory is the primary stock driver: the April end‑of‑review meeting should clarify whether reformulation (lower DDAIP) or additional nonclinical work is required; watch for a defined remediation plan and timelines .
  • Near‑term cash sufficiency mitigates financing risk through 2018, but prolonged regulatory work could necessitate future capital or strategic transactions; management is proactively exploring business combinations .
  • Sequential P&L improvement in Q4 (smaller net loss vs Q3) provides some cushion while regulatory steps are taken, though YoY deterioration underscores sensitivity to milestone/CMC costs .
  • Allergan commercialization option is on pause until approval; any positive regulatory inflection could rapidly re‑activate commercialization optionality or third‑party partnering interest .
  • Monitor disclosures around DDAIP concentration and any bridging study requirements; clarity here will determine development cost, timeline, and probability of approval .
  • RayVa partnering remains a secondary lever; potential transactions could provide non‑dilutive funding or pipeline diversification while Vitaros path is resolved .
  • With consensus estimates unavailable, price action will likely hinge on qualitative regulatory signals and liquidity visibility rather than traditional beat/miss dynamics in the near term [GetEstimates attempt error].

Appendix: Additional References

  • Q4 2017 press release (8‑K 2.02): financials, cash, CRL details .
  • Q4 2017 earnings call transcript: CRL, DDAIP safety, cash runway, Allergan updates .
  • Q3 2017 corporate update: resubmission acknowledged, PDUFA date set, cash and expenses .
  • Q2 2017 corporate update: final NDA draft complete, expected resubmission, cash and expenses .